TNSN97201A1 - Peptides et composes se liant a un recepteur - Google Patents

Peptides et composes se liant a un recepteur

Info

Publication number
TNSN97201A1
TNSN97201A1 TNTNSN97201A TNSN97201A TNSN97201A1 TN SN97201 A1 TNSN97201 A1 TN SN97201A1 TN TNSN97201 A TNTNSN97201 A TN TNSN97201A TN SN97201 A TNSN97201 A TN SN97201A TN SN97201 A1 TNSN97201 A1 TN SN97201A1
Authority
TN
Tunisia
Prior art keywords
compounds
peptides
receptor
bind
radiotherapy
Prior art date
Application number
TNTNSN97201A
Other languages
English (en)
Inventor
Balasubramanian Palaniappan
E Cwirla Steven
E Dower William
Wayne Hendren Richard
J Schatz Peter
Qun Yin
W Barrett Ronald
B Deprince Randolph
M Gates Christian
Podduturi Surekha
R Wagstrom Christopher
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN97201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TNSN97201A1 publication Critical patent/TNSN97201A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SONT DECRITS DES PEPTIDES ET DES COMPOSES QUI FIXENT ET ACTIVENT LE RECEPTEUR DE THROMBOPOIETINE. DE TELS PEPTIDES ET COMPOSES SONT UTILES DANS LES METHODES POUR LE TRAITEMENT D'AFFECTIONS HEMATOLOGIQUES ET PLUS PARTICULIEMENT DE LA THROMBOCYTOPENIE RESULTANT DE LA CHIMIOTHERAPIE, DE LA RADIOTHERAPIE OU DE TRANSFUSIONS DE MOELLE OSSEUSE, AINSI QUE DANS LES METHODES DE DIAGNOSTIC FAISANT APPEL A DES PEPTIDES ET COMPOSES MARQUES.
TNTNSN97201A 1996-12-11 1997-12-10 Peptides et composes se liant a un recepteur TNSN97201A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor

Publications (1)

Publication Number Publication Date
TNSN97201A1 true TNSN97201A1 (fr) 2005-03-15

Family

ID=25071323

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97201A TNSN97201A1 (fr) 1996-12-11 1997-12-10 Peptides et composes se liant a un recepteur

Country Status (24)

Country Link
US (2) US5869451A (fr)
EP (3) EP2028191A1 (fr)
JP (1) JP4128225B2 (fr)
KR (3) KR100668546B1 (fr)
CN (1) CN100379760C (fr)
AR (2) AR010752A1 (fr)
AT (1) ATE420893T1 (fr)
AU (1) AU725731B2 (fr)
BR (1) BRPI9713914B1 (fr)
CA (1) CA2274149C (fr)
CO (1) CO5080768A1 (fr)
DE (1) DE69739219D1 (fr)
ES (1) ES2321038T3 (fr)
HR (1) HRP970683B1 (fr)
MA (1) MA26454A1 (fr)
PA (1) PA8442601A1 (fr)
PE (1) PE27599A1 (fr)
SV (1) SV1997000104A (fr)
TN (1) TNSN97201A1 (fr)
TR (2) TR199901971T2 (fr)
TW (1) TW515804B (fr)
UY (1) UY24805A1 (fr)
WO (1) WO1998025965A2 (fr)
ZA (1) ZA9711045B (fr)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1961760A3 (fr) * 1995-06-07 2008-09-03 Glaxo Group Limited Peptides et composés se liant à un récepteur de la thrombopoïétine
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP1039906B1 (fr) 1997-10-31 2008-02-27 Smithkline Beecham Corporation complexes metalliferes avec des effets antibacteriens et antifongiques
JP2001521897A (ja) * 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
EP1032387B1 (fr) 1997-10-31 2007-03-07 Smithkline Beecham Corporation Nouveaux complexes metalliques
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
CZ302155B6 (cs) 1998-10-23 2010-11-18 Kirin-Amgen Inc. Sloucenina, která se váže na mpl receptor, zpusob její výroby, farmaceutická kompozice s jejím obsahem, polynukleotid, vektor a hostitelská bunka
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP2003514524A (ja) 1999-11-18 2003-04-22 コルバス・インターナショナル・インコーポレイテッド エントセリアーゼをコードしている核酸、エンドセリアーゼおよびその使用
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001259432B2 (en) * 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE414720T1 (de) 2000-12-05 2008-12-15 Alexion Pharma Inc Rationell entworfene antikörper
WO2002072786A2 (fr) 2001-03-13 2002-09-19 Corvas International, Inc. Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (fr) 2001-03-27 2002-10-03 Dendreon San Diego Llc Molecules d'acide nucleique codant une serine protease transmembranaire 9, polypeptides codes et procedes fondes sur ces derniers
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
DE50205310D1 (de) * 2002-06-29 2006-01-19 Aquanova Ger Solubilisate Tech Isoflavonkonzentrate sowie verfahren zu ihrer herstellung
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
EP1552828A4 (fr) 2002-08-14 2007-01-24 Nissan Chemical Ind Ltd Activateur du recepteur de la thrombopoietine et procede de production
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
KR20050093759A (ko) * 2002-09-18 2005-09-23 오르토-맥네일 파마슈티칼, 인코퍼레이티드 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
JP2006522022A (ja) 2003-02-14 2006-09-28 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ プロテアソーム干渉に関連する避妊法および組成物
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
WO2004100997A2 (fr) * 2003-05-12 2004-11-25 Affymax, Inc. Nouveau fragment espaceur de composes peptidiques modifies par du poly(ethylene glycol)
AU2004238869B2 (en) 2003-05-12 2009-06-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
PL1629007T3 (pl) * 2003-05-12 2009-09-30 Affymax Inc Nowe peptydy wiążące się z receptorem erytropoetyny
AU2004263442B2 (en) * 2003-08-12 2008-05-29 Shionogi & Co., Ltd. Compounds having thrombopoietin receptor agonism
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
HUE032370T2 (en) * 2003-08-28 2017-09-28 Janssen Pharmaceuticals Inc Peptides and compounds that bind to thrombopoietin receptors
ES2295961T3 (es) 2003-12-31 2008-04-16 F. Hoffmann-La Roche Ag Proceso para la sintesis peptidica utilizacndo una cantidad reducida de agente de desproteccion.
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2005082005A2 (fr) * 2004-02-20 2005-09-09 Biosurface Engineering Technologies, Inc., Et Al. Modulateur positif de la proteine 2 morphogenique osseuse
MX2007000216A (es) * 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
WO2006036834A2 (fr) * 2004-09-24 2006-04-06 Amgen Inc. Molecules fc modifiees
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (fr) * 2004-11-11 2006-06-15 Affymax, Inc. Nouveaux peptides se liant au recepteur de l'erythropoietine
RU2395505C2 (ru) 2004-12-08 2010-07-27 Ниссан Кемикал Индастриз, ЛТД 3-этилиденгидразино-замещенные гетероциклические соединения в качестве активаторов рецептора тромбопоэтина
WO2006064957A1 (fr) 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. Compose d’amide et activateur du recepteur de la thrombopoietine
EP1861417B1 (fr) 2005-03-10 2013-05-15 BioNTech AG Microproteines dimeriques ou multimeriques
WO2006094530A1 (fr) * 2005-03-11 2006-09-14 Siegfried Ltd. Conjugues de proteines et de dipolymeres et leurs procedes de preparation
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP2008546732A (ja) * 2005-06-23 2008-12-25 アプラゲン ゲーエムベーハー 多価化合物
EP1904472A1 (fr) 2005-07-15 2008-04-02 Nissan Chemical Industries, Ltd. Composes thiophenes et activateurs du recepteur thrombopoietine
KR101290484B1 (ko) 2005-07-20 2013-07-26 닛산 가가쿠 고교 가부시키 가이샤 피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1947101A4 (fr) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd Composé de type hydrazide et activateur du récepteur de la thrombopoïétine
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
WO2007087428A2 (fr) * 2006-01-25 2007-08-02 Amgen Inc. Composes thrombopoietiques
EP1834963A1 (fr) * 2006-03-13 2007-09-19 Siegfried Ltd. Conjugues de proteines et de dipolymeres et leurs procedes de preparation
PT2005185E (pt) * 2006-03-22 2011-01-27 Viral Logic Systems Technology Corp Métodos para a identificação de alvos polipeptídicos
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2007133811A2 (fr) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Compositions associées au cd47 et procédés destinés au traitement de maladies et de troubles immunologiques
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
JP2009541358A (ja) 2006-06-22 2009-11-26 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成を強化するためにｂｍｐ−２増幅因子／共活性化因子を送達するための組成物および方法
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
JP2010520855A (ja) * 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー
EP2162540A2 (fr) * 2007-05-22 2010-03-17 Amgen Inc. Compositions et procédés pour produire des protéines de fusion bioactives
WO2008157824A2 (fr) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Conjugués de peptides thrombopoïétiques
WO2009029682A1 (fr) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Thérapie de combinaison avec un inhibiteur de la kinase syk
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
EP2247618B1 (fr) 2008-01-25 2014-06-11 Amgen, Inc Anticorps anti-ferroportine et procédés d'utilisation
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
JP2012521360A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
WO2011012306A2 (fr) 2009-07-30 2011-02-03 Aplagen Gmbh Utilisation d'emp pour contrer les effets stimulants de l'epo sur des tumeurs sensibles à l'epo, tout en maintenant l'érythropoïèse
US8889732B2 (en) 2009-10-23 2014-11-18 Nissan Chemical Industries, Ltd. Fused heterocyclic compounds and thrombopoietin receptor activators
WO2011098095A1 (fr) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides se liant au récepteur de tpo
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
WO2014159242A1 (fr) 2013-03-14 2014-10-02 Novartis Ag Mutants de notch 3 et leurs utilisations
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
KR102330652B1 (ko) 2014-09-11 2021-11-23 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 및 cd80 (b7-1)/pd-li 단백질/단백질 상호작용의 마크로시클릭 억제제
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
RU2758608C2 (ru) 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
EP3827849A1 (fr) 2016-05-19 2021-06-02 Bristol-Myers Squibb Company Immunomodulateurs pour l'imagerie tep
CN110267971B (zh) 2016-11-07 2023-12-19 百时美施贵宝公司 免疫调节剂
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
CA3070442A1 (fr) * 2017-07-26 2019-01-31 Janssen Pharmaceutica Nv Procedes de protection de l'integrite vasculaire induite par une radiotherapie ciblee
KR20200058506A (ko) 2017-10-03 2020-05-27 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US11273203B2 (en) 2019-01-25 2022-03-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
US20200237872A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
WO2020154585A1 (fr) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
WO2023056444A1 (fr) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Procédés d'augmentation de la production de cellules progénitrices

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) * 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
CA2136434C (fr) * 1992-06-11 2008-12-02 Howard Bernstein Systemes pour la liberation d'un medicament a base d'erythropoietine
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1995005843A1 (fr) 1993-08-25 1995-03-02 Systemix, Inc. Procede de production d'une population de cellules souches hematopoietiques fortement enrichie
WO1995011922A1 (fr) * 1993-10-29 1995-05-04 Affymax Technologies N.V. Banques de presentation de peptides et d'anticorps in vitro
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021919A2 (fr) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Proteine a activite de thrombopoietine (tpo)
EP0668352A1 (fr) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protéine à activité TPO
AU1843595A (en) * 1994-02-14 1995-08-29 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
AU691828B2 (en) * 1994-02-14 1998-05-28 University Of Washington Hematopoietic protein and materials and methods for making it
WO1995026746A1 (fr) * 1994-03-31 1995-10-12 Amgen Inc. Compositions et methodes de stimulation de la croissance et de la differentiation des megacaryocytes
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
WO1996017062A1 (fr) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Thrombopoietine de faible poids moleculaire
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
ATE346096T1 (de) * 1995-04-26 2006-12-15 Kyowa Hakko Kogyo Kk G-csf tpo fusionsproteine
EP1961760A3 (fr) 1995-06-07 2008-09-03 Glaxo Group Limited Peptides et composés se liant à un récepteur de la thrombopoïétine
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체

Also Published As

Publication number Publication date
HRP970683B1 (en) 2002-10-31
BR9713914A (pt) 2000-02-29
JP2001505898A (ja) 2001-05-08
ES2321038T3 (es) 2009-06-01
AR062931A2 (es) 2008-12-17
KR20000069408A (ko) 2000-11-25
TR199901971T2 (xx) 1999-12-21
AU725731B2 (en) 2000-10-19
ATE420893T1 (de) 2009-01-15
DE69739219D1 (de) 2009-03-05
PA8442601A1 (es) 2000-05-24
KR100668546B1 (ko) 2007-01-16
KR100625708B1 (ko) 2006-09-20
CA2274149A1 (fr) 1998-06-18
TW515804B (en) 2003-01-01
CN100379760C (zh) 2008-04-09
BRPI9713914B1 (pt) 2017-06-20
EP0948539B1 (fr) 2009-01-14
AR010752A1 (es) 2000-07-12
TR200401638T2 (tr) 2004-11-22
WO1998025965A3 (fr) 1998-08-13
CA2274149C (fr) 2008-07-15
AU5854798A (en) 1998-07-03
PE27599A1 (es) 1999-03-29
JP4128225B2 (ja) 2008-07-30
US6121238A (en) 2000-09-19
EP2028191A1 (fr) 2009-02-25
SV1997000104A (es) 1998-09-18
KR100679576B1 (ko) 2007-02-07
KR20050042505A (ko) 2005-05-09
CO5080768A1 (es) 2001-09-25
HRP970683A2 (en) 1998-10-31
UY24805A1 (es) 2000-12-29
EP0948539A2 (fr) 1999-10-13
ZA9711045B (en) 1999-06-09
CN1245504A (zh) 2000-02-23
KR20060025611A (ko) 2006-03-21
EP2336165A1 (fr) 2011-06-22
US5869451A (en) 1999-02-09
BRPI9713914B8 (fr) 2021-05-25
WO1998025965A2 (fr) 1998-06-18
MA26454A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
TNSN97201A1 (fr) Peptides et composes se liant a un recepteur
Weis et al. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.
US4676980A (en) Target specific cross-linked heteroantibodies
Nicholson-Weller et al. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
Fearon Regulation by membrane sialic acid of β1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway
DiSCIPIO The binding of human complement proteins C5, factor B, β1H and properdin to complement fragment C3b on zymosan
Rother et al. The complement system
Kao et al. Quantitative analysis of platelet surface HLA by W6/32 anti-HLA monoclonal antibody
Yamamoto et al. Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation
Kinoshita et al. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
Medof et al. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
Blue et al. Evidence for specific association between class I major histocompatibility antigens and the CD8 molecules of human suppressor/cytotoxic cells
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
Misasi et al. Human complement factor H: An additional gene product of 43kDa isolated from human plasma shows cofactor activity for the cleavage of the third component of complement
Fujita et al. Solubilization of immune precipitates by six isolated alternative pathway proteins.
Tefferi et al. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells
Medof et al. Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells.
Hong et al. Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system.
Sundsmo et al. Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading.
Peerschke et al. C1q augments platelet activation in response to aggregated Ig.
Hutt-Fletcher et al. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Seya et al. Additional forms of human decay-accelerating factor (DAF).
Ogura et al. Localization and biosynthesis of functional thrombomodulin in human megakaryocytes and a human megakaryoblastic cell line (MEG-01)
Parker et al. Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes.
Tanaka et al. The origin of metallothionein in red blood cells